|
시장보고서
상품코드
2086957
고강도 집속 초음파(HIFU) 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)High-Intensity Focused Ultrasound - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
고강도 집속 초음파 시장 요약
고강도 집속 초음파(HIFU)는 비침습적이고 절개를 수반하지 않는 치료 기술로, 체내 깊은 곳에 위치한 표적 부위에 초음파 에너지를 집중시켜 조직 온도를 상승시킴으로써 주변 조직을 보존하면서 병변 조직을 정밀하게 절제합니다. 초음파 영상 진단 또는 자기공명영상(MRI)을 통한 실시간 유도 하에, HIFU는 절개나 이온화 방사선을 사용하지 않고 열 절제를 수행하므로 외래 치료가 가능하며 회복도 빠릅니다. 이 기술은 국소성 전립선암의 국소적 절제, 자궁근종 치료, 경두개 자기공명영상(MRI) 유도 하에 집속 초음파를 이용한 본태성 진전 및 파킨슨병 등의 신경 질환 치료, 종양 절제, 나아가 피부 탄력 개선 등의 미용 및 피부과적 시술 등, 점점 더 폭넓은 임상 용도로 활용되고 있습니다. 이 시장은 초음파 유도식 및 자기공명영상(MRI) 유도식 시스템, 비침습적 및 저침습적 접근법, 그리고 병원, 외래수술센터(ASC), 전문 클리닉, 연구 기관 등의 최종 사용자에 걸쳐 있습니다. Sonablate, Focal One, Exablate, TULSA-PRO와 같은 시스템을 핵심으로 하여, 암 발병률 증가, 장기 보존 치료에 대한 수요 증가, 신경 질환 분야로의 확대, 그리고 보험 급여 개선에 힘입어 HIFU는 비침습적·영상 유도 치료 분야에서 가장 유망한 신흥 분야 중 하나로 부상하고 있습니다.
고강도 집속 초음파(HIFU) 시장의 주요 성장 동인
고강도 집속 초음파(HIFU) 시장의 주요 기업
경쟁 구도는 다음과 같은 활발한 개발 및 공급 기업들에 의해 주도되고 있습니다.
고강도 집속 초음파 시장의 성장에 기여하는 요인
시장 성장 촉진요인
세계 암 부담 증가 및 종양 절제술에 대한 수요
HIFU 시장의 가장 강력한 촉진요인은 세계 암 부담 증가와 비침습적 종양 절제술에 대한 강력한 수요입니다. 국제암연구소(IARC)는 2022년에 2,000만 건의 신규 암 사례가 기록되었으며, 2050년까지 3,500만 건에 달할 것으로 예측하고 있으며, 암은 여전히 세계 주요 사망 원인 중 하나입니다. HIFU는 절개 없이 정밀한 종양 열 절제를 가능하게 합니다. 특히 국소성 전립선암에서 그 효과가 두드러지며, 이 집중 치료를 통해 주변 조직을 보존하면서 종양 또는 전립선의 일부를 파괴할 수 있으므로, 전립선 전적출술이나 방사선 치료에 수반되는 요실금, 발기부전 및 장 합병증을 경감시킬 수 있습니다. 이 기술은 자궁근종, 간암, 유방암, 췌장암, 기타 종양은 물론, 통증 완화를 목적으로 하는 골전이 치료에도 응용되고 있습니다. 고령화와 진단 기술의 발전에 따라 암 발병률이 증가하고, 환자와 의사가 장기 보존 요법을 점점 더 선호함에 따라 HIFU를 이용한 종양 절제술에 대한 수요가 확대되고 있으며, 이는 예측 기간 동안 시장 성장을 뒷받침하는 요인이 되고 있습니다.
비침습적 및 장기 보존 치료에 대한 수요 증가
비침습적이며 장기를 보존하는 치료법에 대한 수요 증가가 성장의 핵심 동력이 되고 있습니다. HIFU는 절개나 이온화 방사선을 사용하지 않고 피부나 점막을 통해 절제 에너지를 조사하기 때문에 기존의 수술이나 방사선 치료에 비해 외래 치료가 가능하며, 회복이 빠르고, 출혈량이 적으며, 합병증 발생률도 낮습니다. 국소성 전립선암의 경우, 국소성 HIFU는 전립선 전체를 치료하는 방법보다 배뇨 기능 및 성기능 보존 측면에서 훨씬 뛰어난 효과를 발휘합니다. 또한, 자궁근종 및 기타 질환에 대해서는 자궁 적출술이나 개복 수술을 대체할 수 있는 자궁 보존이 가능한 당일 퇴원 치료 옵션을 제공합니다. 환자들은 입원 기간, 흉터, 장기적인 부작용을 최소화하는 치료법을 점점 더 요구하고 있으며, 의료 제도 측면에서도 합병증 감소와 회복 속도 향상을 통해 전체 의료비 절감 효과가 높이 평가되고 있습니다. HIFU는 반복 시술이 가능하고 환자의 내약성도 높기 때문에 외래 및 통원 치료 현장에 도입이 촉진되고 있습니다. 전문 분야를 불문하고, 저침습적이며 삶의 질(QOL)을 유지할 수 있는 치료법에 대한 선호도가 높아짐에 따라 HIFU에 대한 수요가 확대되고 있으며, 이는 예측 기간 동안 시장 성장을 뒷받침하고 있습니다.
시장 성장 억제요인
강력한 성장세를 보이고 있음에도 불구하고, HIFU 시장은 중대한 제약에 직면해 있습니다. HIFU 플랫폼, 특히 자기공명영상(MRI)실 접근이 필요한 자기공명 유도식 시스템은 막대한 설비 투자와 운영비가 소요되므로, 시스템 및 시술 비용의 높이가 주요 장벽으로 작용하고 있습니다. 이로 인해 도입은 충분한 자금력을 갖춘 병원이나 전문 시설로 제한되고 있습니다. 보험 환급은 개선되는 추세이지만, 많은 지역과 적응증에서 여전히 불균일하고 미성숙한 상황이며, 광범위하고 일관된 보험 적용이 이루어지지 않아 환자의 접근성과 의료 제공업체의 투자 수익률을 제약하고 있습니다. 특정 용도, 특히 일부 자기공명영상(MRI) 유도 시술에서 치료 시간이 길어지면 처리 능력이 저하되어, 장비 1대당 치료할 수 있는 환자 수가 제한됩니다. 임상적 및 해부학적 제약도 존재합니다. HIFU가 모든 종양 부위나 환자의 해부학적 구조에 적합한 것은 아니며, 환자의 움직임이 표적 조준에 영향을 미칠 수 있고, 일부 조직이나 뼈 구조가 에너지 전달을 방해할 수 있습니다. 또한, 일부 적응증에 대해서는 확립된 치료법과의 장기적인 비교 결과 데이터가 아직 성숙 단계에 있습니다. 훈련을 받은 시술자나 전문 시설의 부족이 치료 능력을 제한하고 있으며, 의뢰 의사 및 환자 간의 인지도도 여전히 고르지 않습니다. 냉동 요법, 고주파 절제술, 정위 방사선 치료, 그리고 신기술인 히스토트리프시 등 다른 저침습 및 절제 요법과의 경쟁이 시장 환경을 격화시키고 있습니다. 새로운 적응증에 대한 규제 승인 절차는 장기간 소요되며, 풍부한 근거 자료가 요구됩니다. 이러한 비용, 보험 급여, 처리 능력, 임상적 요인 및 인지도와 같은 장벽들이 복합적으로 작용하여, 비침습적 치료에 대한 수요와 임상적 확대라는 근본적인 촉진요인이 여전히 견조함에도 불구하고 성장 속도는 둔화되고 있습니다.
경쟁 구도는 다음과 같은 관점에서 평가할 수 있습니다.
고강도 집속 초음파 시장 보고서 조사에서 도출된 주요 포인트
본 고강도 집속 초음파 시장 보고서 조사를 통해 혜택을 받을 수 있는 대상 독자
Q1. 고강도 집속 초음파 시장의 성장률은 어느 정도입니까?
고강도 집속 초음파 시장은 2026-2034년 예측 기간 동안 연평균 성장률(CAGR) 8.6%로 확대될 것으로 전망됩니다.
Q2. 고강도 집속 초음파 시장 규모는 어느 정도입니까?
고강도 집속 초음파(HIFU) 시장 규모는 2025년에 14억 5,000만 달러로 평가되었고, 2034년까지 30억 5,000만 달러에 달할 것으로 예측됩니다.
Q3. 고강도 집속 초음파(HIFU) 시장을 주도하는 지역은 어디인가?
북미는 선진적인 인프라, 첨단 기술 도입, 신경계 및 전립선 치료에 대한 보험 적용 확대, 그리고 치료 센터와 개발 기업이 밀집된 기반을 바탕으로 2025년에는 세계 매출의 41%를 차지하며 고강도 집속 초음파 시장을 주도했습니다. 아시아태평양은 예측 기간 동안 가장 빠르게 성장할 지역입니다.
Q4. 고강도 집속 초음파(HIFU) 시장의 주요 성장 동인은 무엇인가?
주요 촉진요인으로는 세계 암 부담 증가를 들 수 있습니다. 국제암연구소(IARC)의 예측에 따르면, 암 환자 수는 2022년 2,000만 명에서 2050년까지 3,500만 명으로 증가할 것으로 전망됩니다. 또한, 비침습적이며 장기 보존이 가능한 치료법에 대한 수요 증가, 본태성 진전에 대한 자기공명영상(MRI) 유도 하의 집속 초음파 치료 등 신경 질환 분야에서의 용도 확대, 일련의 규제 당국으로부터의 승인 잇따른 획득, 그리고 보험 환급 제도의 개선도 주요 촉진요인으로 작용하고 있습니다.
Q5. 고강도 집속 초음파(HIFU) 시장의 주요 기업은?
주요 기업으로는 Insightec Ltd., EDAP TMS S.A., Profound Medical Corp., SonaCare Medical, LLC, Chongqing Haifu Medical Technology Co., Ltd., Theraclion S.A., Alpinion Medical Systems Co., Ltd., Koninklijke Philips N.V., FUSMobile Inc., Arrayus Technologies Inc. 등이 있으며, 기타에도 ‘경쟁 현황’ 섹션에서 소개된 활발한 공급업체가 다수 존재합니다. Insightec사는 신경학 분야를 선도하고 있으며, EDAP TMS사와 SonaCare사는 전립선 HIFU 분야를 선도하고 있습니다.
High-Intensity Focused Ultrasound Market Summary
High-intensity focused ultrasound (HIFU) is a non-invasive, incisionless therapeutic technology that focuses ultrasonic energy onto a targeted point deep within the body to raise tissue temperature and precisely ablate diseased tissue while sparing surrounding structures. Guided in real time by either ultrasound imaging or magnetic resonance imaging, HIFU delivers thermal ablation without incisions or ionizing radiation, enabling outpatient treatment with rapid recovery. The technology is used across a widening range of clinical applications, including focal ablation of localized prostate cancer, treatment of uterine fibroids, neurological indications such as essential tremor and Parkinson's disease through transcranial magnetic-resonance-guided focused ultrasound, tumor ablation, and aesthetic and dermatological procedures such as skin tightening. The market spans ultrasound-guided and magnetic-resonance-guided systems, non-invasive and minimally invasive approaches, and end users including hospitals, ambulatory surgical centers, specialty clinics, and research institutes. Anchored by systems such as Sonablate, Focal One, Exablate, and TULSA-PRO, and propelled by the rising cancer burden, demand for organ-sparing therapy, neurological expansion, and improving reimbursement, HIFU has emerged as one of the most promising frontiers in non-invasive, image-guided therapeutics.
High-Intensity Focused Ultrasound Market Key Growth Drivers
Key Companies in High-Intensity Focused Ultrasound Market
The competitive landscape is led by the following active developers and providers:
Factors Contributing to the Growth of the High-Intensity Focused Ultrasound Market
Market Drivers
Rising Global Cancer Burden and Demand for Tumor Ablation
The most powerful driver of the HIFU market is the rising global cancer burden and the strong demand for non-invasive tumor ablation. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, and cancer remains a leading cause of death worldwide. HIFU offers precise, incisionless thermal ablation of tumors, most prominently in localized prostate cancer, where focal therapy can destroy either the tumor or a portion of the gland while sparing surrounding tissue, reducing the incontinence, erectile dysfunction, and bowel morbidity associated with whole-gland surgery or radiation. The technology is also applied to uterine fibroids, liver, breast, pancreatic, and other tumors, and to bone metastases for pain palliation. As cancer incidence climbs with aging populations and improving diagnosis, and as patients and physicians increasingly favor organ-sparing options, demand for HIFU tumor ablation expands, anchoring market growth through the forecast period.
Growing Demand for Non-Invasive and Organ-Sparing Therapy
Growing demand for non-invasive, organ-sparing therapy is a central growth engine. HIFU delivers ablative energy through the skin and mucosa without incisions or ionizing radiation, enabling outpatient treatment, rapid recovery, minimal blood loss, and low complication rates compared with conventional surgery and radiotherapy. For localized prostate cancer, focal HIFU preserves continence and potency far better than whole-gland treatment, and for uterine fibroids and other conditions it offers a uterus-sparing, day-case alternative to hysterectomy or open surgery. Patients increasingly seek treatments that minimize hospitalization, scarring, and long-term side effects, and health systems value the reduced complications and faster recovery that lower overall care costs. The repeatable and well-tolerated nature of HIFU supports its integration into outpatient and ambulatory settings. As preference for minimally invasive, quality-of-life-preserving therapy grows across specialties, demand for HIFU expands, reinforcing market growth across the forecast period.
Market Restraints
Despite strong momentum, the HIFU market faces material constraints. High system and procedure costs are a primary barrier, as HIFU platforms, particularly magnetic-resonance-guided systems that require access to magnetic resonance imaging suites, involve substantial capital investment and operating expense, limiting adoption to well-resourced hospitals and specialized centers. Reimbursement, although improving, remains uneven and immature across many geographies and indications, and the absence of broad or consistent coverage constrains patient access and the return on investment for providers. Long treatment times for certain applications, particularly some magnetic-resonance-guided procedures, reduce throughput and limit the number of patients treated per system. Clinical and anatomical limitations also apply, as HIFU is not suitable for all tumor locations or patient anatomies, patient movement can affect targeting, and some tissues and bony structures impede energy delivery, while long-term comparative outcomes data against established therapies are still maturing for several indications. A shortage of trained operators and specialized centers limits capacity, and awareness among referring physicians and patients remains uneven. Competition from other minimally invasive and ablative modalities, including cryotherapy, radiofrequency ablation, stereotactic radiotherapy, and emerging histotripsy, intensifies the landscape. Regulatory pathways for new indications are lengthy and evidence-intensive. Together, these cost, reimbursement, throughput, clinical, and awareness barriers temper the pace of growth, even as the underlying drivers of non-invasive therapy demand and clinical expansion remain firmly intact.
High-Intensity Focused Ultrasound Market Segment Analysis
The High-Intensity Focused Ultrasound Market by Application (Oncology, Uterine Fibroids, Neurological Disorders, Aesthetics and Dermatology, Others), Guidance Technology (Ultrasound-Guided HIFU, Magnetic-Resonance-Guided HIFU), Method (Non-Invasive, Minimally Invasive), End User (Hospitals, Ambulatory Surgical Centers and Specialty Clinics, Diagnostic and Imaging Centers, Research Institutes), and Geography (North America, Europe, Asia-Pacific, Rest of World).
By Application
Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.
Dominant: Oncology ~ 52%
The oncology segment accounted for 52% of the High-Intensity Focused Ultrasound market in 2025. Oncology is the leading application because HIFU's core clinical value lies in the non-invasive, organ-sparing ablation of tumors, most prominently localized prostate cancer. Focal HIFU destroys the tumor or a portion of the prostate while preserving continence and potency far better than whole-gland surgery or radiation, and dedicated systems such as Sonablate, Focal One, Exablate Prostate, and TULSA-PRO anchor a large and growing prostate-cancer segment. Beyond the prostate, HIFU ablates liver, breast, pancreatic, kidney, and other tumors and palliates bone-metastasis pain, broadening its oncology footprint. The rising global cancer burden, growing preference for organ-sparing therapy, and expanding clinical evidence reinforce the segment's dominance. Neurological disorders form the fastest-growing application, while uterine fibroids and aesthetic and dermatological procedures are large and established segments. Nonetheless, the scale, clinical value, and breadth of tumor-ablation applications secure the leadership of oncology across the forecast period.
By Guidance Technology
Dominant Subsegment: Ultrasound-Guided HIFU. The ultrasound-guided HIFU category is expected to dominate the market.
Dominant: Ultrasound-Guided HIFU ~ 58%
The ultrasound-guided HIFU segment accounted for 58% of the High-Intensity Focused Ultrasound market in 2025. Ultrasound-guided HIFU is the leading guidance technology because it is more widely deployed, more affordable, and more accessible than magnetic-resonance-guided systems, which require costly access to magnetic resonance imaging suites. Ultrasound guidance provides real-time imaging integrated directly into the treatment system, enabling efficient, lower-cost procedures in urology, gynecology, and general tumor ablation, and it underpins widely used prostate systems such as Sonablate and Focal One as well as many fibroid and tumor-ablation platforms. Its lower capital and operating costs support broader adoption across hospitals, ambulatory centers, and clinics. Magnetic-resonance-guided HIFU is a large and fast-growing segment, essential for neurological applications and valued for superior soft-tissue visualization and real-time thermometry, exemplified by Exablate Neuro and TULSA-PRO. While magnetic-resonance-guided systems grow rapidly in neurology, the accessibility, affordability, and installed base of ultrasound-guided HIFU secure its leadership across the forecast period.
By End User
Dominant Subsegment: Hospitals. The hospitals category is expected to dominate the market.
Dominant: Hospitals ~ 43%
The hospitals segment accounted for 43% of the High-Intensity Focused Ultrasound market in 2025. Hospitals are the leading end user because HIFU systems, particularly magnetic-resonance-guided platforms, require substantial capital investment, specialized infrastructure, and multidisciplinary teams that large hospitals and academic medical centers are best positioned to provide. Hospitals treat the most complex cases across urology, neurology, and gynecology, integrate HIFU into comprehensive cancer and neurology programs, and serve as the primary sites for new indications and clinical studies, anchoring their large share. Leading institutions adopt HIFU to differentiate their offerings and meet patient demand for non-invasive options. Ambulatory surgical centers and specialty clinics form a large and fast-growing segment, particularly for prostate focal therapy and aesthetic procedures that suit outpatient, lower-cost settings, while diagnostic and imaging centers and research institutes support magnetic-resonance-guided treatment and clinical development. While ambulatory and specialty settings grow quickly, the infrastructure, case complexity, and clinical breadth of hospitals secure their leadership across the forecast period.
High-Intensity Focused Ultrasound Market Region Analysis
Dominant Region: North America
North America accounted for 41% of the global High-Intensity Focused Ultrasound market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high adoption of innovative medical technology, strong reimbursement momentum for neurological and prostate applications, and the presence of leading HIFU developers and treatment centers, particularly in the United States. North America leads in magnetic-resonance-guided focused ultrasound for essential tremor and Parkinson's disease, in robotic focal prostate therapy with systems such as Focal One and Sonablate, and in clinical research expanding HIFU into new indications. The region benefits from high healthcare spending, a large base of academic medical centers and specialized treatment sites, active clinical trials, and growing payer coverage. Strong infrastructure, technology adoption, and reimbursement progress anchor the region's continued leadership across the forecast period.
Dominant: North America ~ 41% (Largest)
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the High-Intensity Focused Ultrasound market. The region's elevated CAGR is driven by a large and rising cancer burden, expanding healthcare access and investment, growing adoption of non-invasive therapy, and strong regional developers across China, Japan, South Korea, and India. China is a major center of HIFU innovation and use, home to Chongqing Haifu Medical Technology, a pioneer of ultrasound-guided HIFU for tumor ablation, and the region benefits from large patient populations, government investment in advanced healthcare, and expanding treatment capacity. Rising prostate cancer and uterine fibroid prevalence, growing neurological application, and increasing adoption of aesthetic HIFU further accelerate demand. The combination of high disease burden, healthcare investment, and local innovation positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 41% of the global High-Intensity Focused Ultrasound market revenue in 2025. The United States dominates on the strength of advanced infrastructure, high technology adoption, growing reimbursement for neurological and prostate applications, a dense base of treatment centers, and active clinical research, while Canada contributes through neurological and prostate HIFU adoption and the presence of Profound Medical.
Europe
Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong adoption of focal prostate therapy and neurological focused ultrasound, active clinical research, the presence of developers such as EDAP TMS and Theraclion, and expanding reimbursement, including favorable coverage recommendations for magnetic-resonance-guided focused ultrasound in several countries.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by a large and rising cancer burden, expanding healthcare access and investment, and strong regional developers across China, Japan, South Korea, and India. Chongqing Haifu anchors ultrasound-guided tumor ablation, while growing prostate, fibroid, neurological, and aesthetic applications and large patient populations broaden adoption across the region.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging contributor. Rising cancer and chronic-disease burden, growing interest in non-invasive therapy, and adoption of prostate and aesthetic HIFU in premium private centers, particularly in the Gulf states, are creating early demand, while broader adoption awaits stronger reimbursement, infrastructure, and trained-operator capacity across these markets over the forecast period.
High-Intensity Focused Ultrasound Market Competitive Landscape
The High-Intensity Focused Ultrasound market is classified as Moderately Concentrated. A group of specialized leaders, including Insightec, EDAP TMS, Profound Medical, SonaCare Medical, and Chongqing Haifu, holds a substantial share across the principal application areas of neurology, prostate, and tumor ablation, while a broad field of regional and application-focused developers, including Theraclion, Alpinion, FUSMobile, Arrayus, and aesthetic-HIFU providers, competes across indications and geographies, keeping the market competitive and innovation-driven.
The competitive landscape can be evaluated across the following dimensions:
High-Intensity Focused Ultrasound Market Recent Developmental Activities
In November 2025, EDAP TMS S.A., received FDA 510(k) clearance for the latest edition of its Focal One Robotic HIFU system, adding advanced ultrasound imaging, streamlined treatment planning, an optimized user interface, and support for artificial-intelligence-driven ablation-visualization algorithms. Strategic significance: Strengthened EDAP's leadership in robotic focal prostate therapy and advanced AI-assisted HIFU.
In 2025, EDAP TMS S.A., launched the Focal One i at the American Urological Association Annual Meeting, integrating enhanced imaging and workflow capabilities for robotic focal prostate cancer therapy. Strategic significance: Refreshed EDAP's flagship platform and reinforced its position in ultrasound-guided prostate HIFU.
High-Intensity Focused Ultrasound Market Segmentation
High-Intensity Focused Ultrasound Market by Application
High-Intensity Focused Ultrasound Market by Guidance Technology
High-Intensity Focused Ultrasound Market by Method
High-Intensity Focused Ultrasound Market by End User
High-Intensity Focused Ultrasound Market by Geography
Key Takeaways from the High-Intensity Focused Ultrasound Market Report Study
Target audience who can benefit from this high-intensity focused ultrasound market report study
Q1. What is the growth rate of the High-Intensity Focused Ultrasound market?
The High-Intensity Focused Ultrasound market is projected to expand at a CAGR of 8.6% during the forecast period from 2026-2034.
Q2. What is the market size of the High-Intensity Focused Ultrasound market?
The High-Intensity Focused Ultrasound market is estimated at USD 1.45 billion in 2025 and is projected to reach USD 3.05 billion by 2034.
Q3. Which region dominates the High-Intensity Focused Ultrasound market?
North America dominated the High-Intensity Focused Ultrasound market with a 41% share of global revenue in 2025, supported by advanced infrastructure, high technology adoption, growing reimbursement for neurological and prostate applications, and a dense base of treatment centers and developers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the High-Intensity Focused Ultrasound market?
The principal drivers are the rising global cancer burden, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050; growing demand for non-invasive, organ-sparing therapy; expanding neurological applications such as magnetic-resonance-guided focused ultrasound for essential tremor; a wave of regulatory clearances; and improving reimbursement.
Q5. Who are the major players in the High-Intensity Focused Ultrasound market?
The major players include Insightec Ltd., EDAP TMS S.A., Profound Medical Corp., SonaCare Medical, LLC, Chongqing Haifu Medical Technology Co., Ltd., Theraclion S.A., Alpinion Medical Systems Co., Ltd., Koninklijke Philips N.V., FUSMobile Inc., and Arrayus Technologies Inc., among other active providers profiled in the Competitive Landscape section. Insightec leads neurology, while EDAP TMS and SonaCare lead prostate HIFU.
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.